H. Shelton EARP, III,Xiaodong WANG,Stephen V. FRYE,Douglas Kim GRAHAM
申请号：
US15301893
公开号：
US20170202847A1
申请日:
2015.04.03
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention is directed to methods of treating a tumor, in particular human tumors, including administering an effective amount of a MER tyrosine kinase inhibitor (MER TKI) to inhibit TKI signaling in a tumor. The use of a MER TKI in combination with a chemotherapeutic agent, wherein the MER TKI can be administered to a host with a cancer prior to, during, or after administration with a chemotherapeutic agent, provides for increased anti-tumor effects without an increase in the standard of care dosage of the chemotherapeutic agent.
